Detalhe da pesquisa
1.
Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
; 2024 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583093
2.
Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
Circulation
; 147(25): 1872-1886, 2023 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37154040
3.
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
N Engl J Med
; 384(2): 117-128, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200892
4.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med
; 384(2): 129-139, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200891
5.
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
Am Heart J
; 267: 1-11, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37758044
6.
Sodium-Glucose Cotransporter 2 Inhibitors and Mycotic Genital or Urinary Tract Infections in Heart Failure.
J Card Fail
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38670430
7.
Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
Curr Cardiol Rep
; 26(3): 61-71, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38551786
8.
Putting More Weight on Obesity Trials in Heart Failure.
Curr Heart Fail Rep
; 21(3): 194-202, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38619690
9.
Leveraging electronic health records to streamline the conduct of cardiovascular clinical trials.
Eur Heart J
; 44(21): 1890-1909, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37098746
10.
Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes.
Circulation
; 146(5): 398-411, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35678729
11.
Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
Circulation
; 146(11): 808-818, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603596
12.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation
; 145(19): 1460-1470, 2022 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35394821
13.
Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
Circulation
; 145(21): 1581-1591, 2022 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35510542
14.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966714
15.
Rationale and design of the DAPA-MI trial: Dapagliflozin in patients without diabetes mellitus with acute myocardial infarction.
Am Heart J
; 266: 188-197, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37648579
16.
Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) - Diabetes: rationale and design.
Am Heart J
; 256: 2-12, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36279931
17.
Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.
Diabetes Obes Metab
; 25(6): 1453-1463, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700416
18.
Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial.
Diabetes Obes Metab
; 25(7): 1932-1941, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36945734
19.
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Sleep Breath
; 27(2): 669-672, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35596030
20.
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Eur Heart J
; 43(31): 2958-2967, 2022 08 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34427295